Sangamo Therapeutics, Inc.
SGMO
$0.6223
-$0.0309-4.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.80M | 52.29M | 12.28M | 18.76M | 176.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.80M | 52.29M | 12.28M | 18.76M | 176.23M |
| Cost of Revenue | 111.52M | 138.75M | 168.11M | 202.53M | 230.46M |
| Gross Profit | -53.72M | -86.46M | -155.83M | -183.78M | -54.23M |
| SG&A Expenses | 44.63M | 48.06M | 53.33M | 53.40M | 60.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.15M | 186.81M | 221.44M | 255.93M | 290.52M |
| Operating Income | -98.35M | -134.52M | -209.16M | -237.17M | -114.29M |
| Income Before Tax | -98.11M | -134.85M | -248.51M | -333.22M | -262.90M |
| Income Tax Expenses | -167.00K | -12.00K | 1.17M | -5.17M | -5.07M |
| Earnings from Continuing Operations | -97.94 | -134.84 | -249.68 | -328.05 | -257.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.94M | -134.84M | -249.68M | -328.05M | -257.83M |
| EBIT | -98.35M | -134.52M | -209.16M | -237.17M | -114.29M |
| EBITDA | -93.24M | -128.83M | -199.19M | -224.19M | -99.23M |
| EPS Basic | -0.51 | -0.74 | -1.37 | -1.86 | -1.46 |
| Normalized Basic EPS | -0.30 | -0.44 | -0.69 | -0.80 | -0.35 |
| EPS Diluted | -0.52 | -0.74 | -1.37 | -1.86 | -1.47 |
| Normalized Diluted EPS | -0.30 | -0.44 | -0.69 | -0.80 | -0.35 |
| Average Basic Shares Outstanding | 802.82M | 770.25M | 739.08M | 709.46M | 697.65M |
| Average Diluted Shares Outstanding | 808.80M | 776.23M | 739.08M | 709.46M | 698.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
